NCT01437449View on ClinicalTrials.gov

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 11, 2018

Study Completion Date

August 31, 2019

Conditions
Head and Neck Cancer
Interventions
DRUG

Docetaxel

30 mg/m² by intravenous (IV) administration

DRUG

Cisplatin

30 mg/m² by intravenous (IV) administration

DRUG

Cetuximab

400 mg/m² by intravenous (IV) administration, thereafter 250 IV

DRUG

Carboplatin

Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration

Trial Locations (2)

95305

Stanford University, School of Medicine, Stanford

95616

University of California Davis Medical Center, Davis

All Listed Sponsors
lead

Stanford University

OTHER

NCT01437449 - Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Biotech Hunter | Biotech Hunter